-
A Phase I Dose-Escalation Study of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Oral Dose of Tigulixostat
11 Dec 2025 13:44 GMT
… Further investigations into sex-specific pharmacokinetics, as demonstrated in studies … An evaluation of sex-specific pharmacokinetics and bioavailability of kokusaginine: … GA, Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet. 1986 …
-
The Bidirectional Mechanism of Uric Acid Levels on Alzheimer’s Disease: A Narrative Review
16 Dec 2025 11:49 GMT
… , et al. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors …
-
argenx to discontinue Phase III trials of thyroid eye disease therapy
16 Dec 2025 11:27 GMT
… at assessing the safety, efficacy, pharmacokinetics, tolerability, pharmacodynamics, and immunogenicity of …
-
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
16 Dec 2025 10:15 GMT
… to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response.
About Quince …
-
<![CDATA[FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer]]>
16 Dec 2025 08:21 GMT
… survival, ORR, duration of response, pharmacokinetics, and safety.
Safety of the …
-
Boosting PD-1 Response in Liver Cancer with Apatinib
16 Dec 2025 06:48 GMT
… this treatment paradigm.
Understanding the pharmacokinetics and dynamics of Apatinib in …
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
16 Dec 2025 03:09 GMT
… response rate, duration of response, pharmacokinetics and safety. The investigational arm …
-
<![CDATA[FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer]]>
15 Dec 2025 22:42 GMT
… survival, ORR, duration of response, pharmacokinetics, and safety. Patients receiving T …
-
<![CDATA[FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2-Positive Metastatic Breast Cancer]]>
15 Dec 2025 21:47 GMT
… or death; patient-reported tolerability; pharmacokinetics; and safety.
Progression-Free Survival …
-
<![CDATA[FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in R/R Myeloma]]>
15 Dec 2025 21:33 GMT
… (OS), symptom score, safety, and pharmacokinetics/immunogenicity.
What additional data …